152 related articles for article (PubMed ID: 34282625)
1. Impact of proactive low-molecular weight heparin therapy on outcomes in COVID-1.
Gormez S; Gumusel HK; Ekicibasi E; Degirmencioglu A; Paudel A; Akan G; Atalar F; Erdim R; Eroglu E; Dagdelen S; Sariguzel N; Kirisoglu CE; Pamukcu B
Bratisl Lek Listy; 2021; 122(8):582-589. PubMed ID: 34282625
[TBL] [Abstract][Full Text] [Related]
2. Low-molecular-weight heparin use in coronavirus disease 2019 is associated with curtailed viral persistence: a retrospective multicentre observational study.
Pereyra D; Heber S; Schrottmaier WC; Santol J; Pirabe A; Schmuckenschlager A; Kammerer K; Ammon D; Sorz T; Fritsch F; Hayden H; Pawelka E; Krüger P; Rumpf B; Traugott MT; Glaser P; Firbas C; Schörgenhofer C; Seitz T; Karolyi M; Pabinger I; Brostjan C; Starlinger P; Weiss G; Bellmann-Weiler R; Salzer HJF; Jilma B; Zoufaly A; Assinger A
Cardiovasc Res; 2021 Dec; 117(14):2807-2820. PubMed ID: 34609480
[TBL] [Abstract][Full Text] [Related]
3. Venous thromboembolism and bleeding in critically ill COVID-19 patients treated with higher than standard low molecular weight heparin doses and aspirin: A call to action.
Pavoni V; Gianesello L; Pazzi M; Stera C; Meconi T; Frigieri FC
Thromb Res; 2020 Dec; 196():313-317. PubMed ID: 32977129
[TBL] [Abstract][Full Text] [Related]
4. Comparison of standard prophylactic and preemptive therapeutic low molecular weight heparin treatments in hospitalized patients with COVID-19.
Copur B; Surme S; Sayili U; Tuncer G; Zerdali E; Yazla M; Nakir IY; Buyukyazgan A; Kurt-Cinar AR; Balli H; Kurekci Y; Pehlivanoglu F; Sengoz G
Bratisl Lek Listy; 2021; 122(9):626-630. PubMed ID: 34463107
[TBL] [Abstract][Full Text] [Related]
5. Low molecular weight heparin is useful in adult COVID-19 inpatients. Experience during the first Spanish wave: observational study.
Gonzalez-Porras JR; Belhassen-Garcia M; Lopez-Bernus A; Vaquero-Roncero LM; Rodriguez B; Carbonell C; Azibeiro R; Hernandez-Sanchez A; Martin-Gonzalez JI; Manrique JM; Alonso-Claudio G; Alvarez-Navia F; Madruga-Martin JI; Macias-Casanova RP; García-Criado J; Lozano F; Moyano JC; Sanchez-Hernandez MV; Sagredo-Meneses V; Borras R; Bastida JM; Hernández-Pérez G; Chamorro AJ; Marcos M; Martin-Oterino JA
Sao Paulo Med J; 2022; 140(1):123-133. PubMed ID: 34406312
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic dosing of low-molecular-weight heparin may decrease mortality in patients with severe COVID-19 infection.
Canoglu K; Saylan B
Ann Saudi Med; 2020; 40(6):462-468. PubMed ID: 33307734
[TBL] [Abstract][Full Text] [Related]
7. Applicability of bedside ultrasonography for the diagnosis of deep venous thrombosis in patients with COVID-19 and treatment with low molecular weight heparin.
Zhang P; Qu Y; Tu J; Cao W; Hai N; Li S; Qu P; Lv C; Guo R
J Clin Ultrasound; 2020 Nov; 48(9):522-526. PubMed ID: 32757278
[TBL] [Abstract][Full Text] [Related]
8. Risk Benefit Analysis in Reference to use of LMWH in COVID-19.
Samajdar SS; Sam PA; Moitra S; Ray Y; Pal J; Joshi SR; Tripathi SK
J Assoc Physicians India; 2020 Sep; 68(9):52-61. PubMed ID: 32798346
[TBL] [Abstract][Full Text] [Related]
9. The effectiveness of early anticoagulant treatment in Covid-19 patients.
Arslan Y; Yilmaz G; Dogan D; Hasirci M; Cetindogan H; Ocal N; Savasci U; Fidan G; Tasci C
Phlebology; 2021 Jun; 36(5):384-391. PubMed ID: 33243082
[TBL] [Abstract][Full Text] [Related]
10. SARS-CoV-2 and finding of vein thrombosis: can IMPROVE and IMPROVEDD scores predict COVID-19 outcomes?
Greco S; Zenunaj G; Bonsi B; Bella A; Lopreiato M; Luciani F; Pedrini D; Vestita G; Dalla Nora E; Passaro A
Eur Rev Med Pharmacol Sci; 2021 Feb; 25(4):2123-2130. PubMed ID: 33660832
[TBL] [Abstract][Full Text] [Related]
11. Low molecular weight heparin reduces arterial blood lactic acid content and increases estimated glomerular filtration rate in patients with moderate Covid-19 pneumonia.
Ma L; Zeng Y; Zhao B; Xu L; Li J; Zhu T; Mao E
Chin Med J (Engl); 2022 Mar; 135(6):691-696. PubMed ID: 35471480
[TBL] [Abstract][Full Text] [Related]
12. The Potential of Low Molecular Weight Heparin to Mitigate Cytokine Storm in Severe COVID-19 Patients: A Retrospective Cohort Study.
Shi C; Wang C; Wang H; Yang C; Cai F; Zeng F; Cheng F; Liu Y; Zhou T; Deng B; Vlodavsky I; Li JP; Zhang Y
Clin Transl Sci; 2020 Nov; 13(6):1087-1095. PubMed ID: 32881340
[TBL] [Abstract][Full Text] [Related]
13. The Association of Low Molecular Weight Heparin Use and In-hospital Mortality Among Patients Hospitalized with COVID-19.
Shen L; Qiu L; Liu D; Wang L; Huang H; Ge H; Xiao Y; Liu Y; Jin J; Liu X; Wang DW; Peterson ED; He B; Zhou N
Cardiovasc Drugs Ther; 2022 Feb; 36(1):113-120. PubMed ID: 33394360
[TBL] [Abstract][Full Text] [Related]
14. Early treatment with low-molecular-weight heparin reduces mortality rate in SARS-CoV-2 patients.
DE Vito A; Saderi L; Fiore V; Geremia N; Princic E; Fanelli C; Muredda AA; Panu Napodano C; Moi G; Maida I; Fois AG; Sotgiu G; Madeddu G; Babudieri S
Panminerva Med; 2023 Sep; 65(3):286-291. PubMed ID: 35622392
[TBL] [Abstract][Full Text] [Related]
15. Prevention of thrombotic risk in hospitalized patients with COVID-19 and hemostasis monitoring.
Susen S; Tacquard CA; Godon A; Mansour A; Garrigue D; Nguyen P; Godier A; Testa S; Levy JH; Albaladejo P; Gruel Y;
Crit Care; 2020 Jun; 24(1):364. PubMed ID: 32560658
[TBL] [Abstract][Full Text] [Related]
16. Incidence of deep venous thrombosis in COVID-19 hospitalized patients during the first peak of the Italian outbreak.
Baccellieri D; Bertoglio L; Apruzzi L; Ardita V; D'Angelo A; Bossi M; Rinaldi E; Bilman V; Calvisi S; Castagna A; Galli L; Landoni G; Melissano G; Querini PR; Tresoldi M; De Cobelli F; Zangrillo A; Ciceri F; Chiesa R
Phlebology; 2021 Jun; 36(5):375-383. PubMed ID: 33241746
[TBL] [Abstract][Full Text] [Related]
17. Anti Xa activity after high dose LMWH thrombosis prophylaxis in covid 19 patients at the intensive care unit.
Vlot EA; Van den Dool EJ; Hackeng CM; Sohne M; Noordzij PG; Van Dongen EPA
Thromb Res; 2020 Dec; 196():1-3. PubMed ID: 32805623
[TBL] [Abstract][Full Text] [Related]
18. Effect of Enoxaparin on D-dimer levels in hospitalized Corona Virus patients with a comparison of its level in patients with comorbid conditions.
Khaleq MAA
Wiad Lek; 2024; 77(4):828-833. PubMed ID: 38865643
[TBL] [Abstract][Full Text] [Related]
19. D-Dimer May be a Prognostic Hematological Marker for COVID-19: A Retrospective Case Analysis.
Barma P; Tazrean S; Khalil I
Mymensingh Med J; 2021 Oct; 30(4):1177-1182. PubMed ID: 34605494
[TBL] [Abstract][Full Text] [Related]
20. Anticoagulation in COVID-19: Effect of Enoxaparin, Heparin, and Apixaban on Mortality.
Billett HH; Reyes-Gil M; Szymanski J; Ikemura K; Stahl LR; Lo Y; Rahman S; Gonzalez-Lugo JD; Kushnir M; Barouqa M; Golestaneh L; Bellin E
Thromb Haemost; 2020 Dec; 120(12):1691-1699. PubMed ID: 33186991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
